SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

SEGMENT INFORMATION

(17) SEGMENT INFORMATION

The Company operates in one business segment, which focuses on the development and commercialization of innovative therapies for people with serious and life threatening rare diseases and medical conditions. All products are included in one segment because all of the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

	Three Months Ended March 31,
	2017		2016
Net product revenues by product:
Aldurazyme	$	19,355	$	16,445
Firdapse		4,110		4,239
Kuvan		92,346		76,692
Naglazyme		80,558		65,403
Vimizim		105,821		72,578
Total net product revenues	$	302,190	$	235,357

The following table summarizes total revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is based on the location of Genzyme’s headquarters. Although Genzyme sells Aldurazyme worldwide, the revenues earned by the Company based on Genzyme’s net sales are included in the U.S. region, as the transactions are with Genzyme whose headquarters are located in the U.S.

	Three Months Ended March 31,
	2017		2016
Total revenues by geographic region:
United States	$	132,485	$	109,146
Europe		66,019		59,710
Latin America		37,263		18,379
Rest of world		67,978		49,501
Total revenues	$	303,745	$	236,736